ATTOAtento S.A.
- GlobeNewswire
Attovia Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation ...
- GlobeNewswire
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of ATTO-1310 in chronic pruritus of ...
- Analyst Upgrades
Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30
Citigroup analyst Yigal Nochomovitz initiates coverage on Attovia Therapeutics with a Buy rating and announces Price Target of $30. ...
- Analyst Upgrades
LifeSci Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45
LifeSci Capital initiates coverage on Attovia Therapeutics with a Outperform rating and announces Price Target of $45. ...
- Analyst Upgrades
Leerink Partners Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $52
Leerink Partners analyst Thomas Smith initiates coverage on Attovia Therapeutics with a Outperform rating and announces Price Target of $52. ...
- Analyst Upgrades
RBC Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45
RBC Capital analyst Brian Abrahams initiates coverage on Attovia Therapeutics with a Outperform rating and announces Price Target of $45. ...
- Analyst Upgrades
Morgan Stanley Initiates Coverage On Attovia Therapeutics with Overweight Rating, Announces Price Target of $39
Morgan Stanley analyst Judah Frommer initiates coverage on Attovia Therapeutics with a Overweight rating and announces Price Target of $39. ...
- GlobeNewswire
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for ...
- PR Newswire
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq... ...
- PR Newswire
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq... ...
- GlobeNewswire
Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering
SAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for ...
- SEC
25-NSE Form - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities - Atento S.A. (0001606457) (Subject)
Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities ...
- PR Newswire
Atento announces drawdown of $17 million in tranche 2 funding under its new interim financing
Tranche 2 upsized by $7 million to provide enhanced financial runway to support Atento's restructuring following substantial interest from existing investorsParticipation in Tranche 2 reflects incremental support for ...
- SEC
6-K Form - Report of foreign issuer [Rules 13a-16 and 15d-16] - Atento S.A. (0001606457) (Filer)
Report of foreign issuer [Rules 13a-16 and 15d-16] ...
- SEC
EFFECT Form - Notice of Effectiveness - Atento S.A. (0001606457) (Filer)
Notice of Effectiveness ...
- SEC
POS AM Form - Post-Effective amendments for registration statement - Atento S.A. (0001606457) (Filer)
Post-Effective amendments for registration statement ...
- SEC
S-8 POS Form - Securities to be offered to employees in employee benefit plans, post-effective amendments - Atento S.A. (0001606457) (Filer)
Securities to be offered to employees in employee benefit plans, post-effective amendments ...
- SEC
S-8 POS Form - Securities to be offered to employees in employee benefit plans, post-effective amendments - Atento S.A. (0001606457) (Filer)
Securities to be offered to employees in employee benefit plans, post-effective amendments ...
- SEC
F-3/A Form - [Amend] Registration statement by foreign private issuers - Atento S.A. (0001606457) (Filer)
[Amend] Registration statement by foreign private issuers ...
- PR Newswire
Atento Announces Delisting from NYSE; Delisting expected in Restructuring Plan
Delisting is contemplated by the previously announced comprehensive financial restructuring plan aimed at optimizing financial and operational efficiency and driving long-term growth. Delisting affects only the shares of ...
- SEC
6-K Form - Report of foreign issuer [Rules 13a-16 and 15d-16] - Atento S.A. (0001606457) (Filer)
Report of foreign issuer [Rules 13a-16 and 15d-16] ...
- SEC
6-K Form - Report of foreign issuer [Rules 13a-16 and 15d-16] - Atento S.A. (0001606457) (Filer)
Report of foreign issuer [Rules 13a-16 and 15d-16] ...
- SEC
6-K Form - Report of foreign issuer [Rules 13a-16 and 15d-16] - Atento S.A. (0001606457) (Filer)
Report of foreign issuer [Rules 13a-16 and 15d-16] ...
- PR Newswire
Atento enters into a restructuring support agreement with certain key financial stakeholders
Atento enters into a restructuring support agreement with certain key financial stakeholders to obtain support for a comprehensive balance sheet restructuringAtento continues to work with additional financial ...
- SEC
6-K Form - Report of foreign issuer [Rules 13a-16 and 15d-16] - Atento S.A. (0001606457) (Filer)
Report of foreign issuer [Rules 13a-16 and 15d-16] ...